Nicotinamide treatment for glaucoma progression
Treatments studied
Part of Eyes & vision clinical trials.
This trial studies whether nicotinamide (a form of vitamin B3/niacin) can slow or affect glaucoma progression. You may be eligible if you have newly diagnosed, untreated glaucoma or if you have treated glaucoma with measurable visual field changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18) with glaucoma that affects the eye’s pressure/nerve pattern, or “glaucoma-like” findings
- Your vision is good enough for testing (at least 6/12 Snellen for the new cases, or at least 6/18 for the treated cases)
- You can do reliable visual field tests at least twice, with good test quality (not too many bad tracking/focus errors)
- Your eye pressure is not too high (no eye above 35 mmHg, and average not high in repeat checks)
- You should not be pregnant or breastfeeding, and you must be able to attend follow-up for the study
- You must avoid starting/using nicotinamide (NAM) supplements during the trial (or do a required washout if you already take it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a vitamin B3 supplement called nicotinamide can help slow down vision loss in people with glaucoma. It is for those with moderate disease who are already on treatment.
This study measures levels of nicotinamide (a form of vitamin B3) in different eye fluids of people with glaucoma and compares them to people without glaucoma. It aims to understand how nicotinamide relates to cell damage and aging in the eye, which could help develop new treatments.
This trial tests whether NAD precursor supplements can improve nerve health and vision in people with glaucoma. If you have glaucoma with mild to moderate vision loss, this study may help understand if these supplements could protect your optic nerve.
This study tests whether metformin can slow damage to the optic nerve in people with glaucoma. It uses eye scans and vision tests to look for changes over time, aiming to help preserve sight.
This trial tests whether a dietary supplement (DHA + citicoline) can help protect vision in people with glaucoma. You may qualify if you have confirmed glaucoma in at least one eye and are between 50 and 75 years old.
This trial tests an investigational eye drop called ASP2767 to see if it is safe and can help slow or prevent further vision loss in people with advanced glaucoma-related optic nerve damage.
Hear when a new Glaucoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.